Clinical Trials

Leukemia, Myeloid, Chronic-Phase, Neoplasm, Residual

NCT05007873 2026-02-18

ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase

Phase 2 Recruiting

70 enrolled

Leukemia, Myeloid, Chronic-Phase

NCT00254423 2026-01-15

Dasatinib in Treating Patients With Early Chronic Phase Chronic Myelogenous Leukemia

150 enrolled 10 charts

Phase 2 Active not recruiting

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT03654768 2025-12-18

Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia

81 enrolled 20 charts

Leukemia, Myeloid, Chronic-Phase

NCT04838041 2025-07-30

Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation

Phase 2 Recruiting

51 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT04126681 2025-03-03

A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase

144 enrolled

Phase 2 Active not recruiting

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT04147533 2024-11-26

HALF

150 enrolled

Substance Withdrawal Syndrome, Leukemia, Myeloid, Chronic-Phase

NCT03625388 2023-09-22

Low Dose Dasatinib (50 mg Daily) as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

56 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT01593254 2023-06-22

DASCERN

262 enrolled 11 charts

Leukemia, Myeloid, Chronic-Phase

NCT05638763 2022-12-06

Cytochrome P450 Inhibition to Decrease Dosage of Dasatinib for Chronic Myelogenous Leukemia

Phase 2 Unknown

15 enrolled

Leukemia, Myeloid, Chronic-Phase

NCT01850004 2022-11-03

DASFREE

84 enrolled 10 charts

Leukemia, Myeloid, Chronic-Phase

NCT01725204 2017-09-25

NordCML007

40 enrolled

Leukemia, Myeloid, Chronic-Phase

NCT00866736 2015-09-15

A Study of Dasatinib in Patients With Imatinib Resistant or Intolerant Chronic Myeloid Leukemia

65 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT00320190 2013-10-30

Study of Dasatinib in Patients With Chronic Phase Chronic Myeloid Leukemia and a Suboptimal Response to Imatinib

Phase 2 Terminated

52 enrolled 8 charts

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT01887561 2013-06-27

Dasatinib for Patients Achieving Complete Molecular Response for Cure D-NewS Trial

Phase 2 Unknown

100 enrolled

Leukemia, Myeloid, Chronic-Phase

NCT00112775 2011-06-07

BMS-354825 or Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Previous Imatinib Mesylate

Phase 2 Unknown